SoftBank, an investment holding company, and Tempus AI, a precision medicine company, agreed to form SB TEMPUS joint venture in a $187m deal. “At Tempus, we are dedicated to transforming the landscape of precision medicine through the practical application of artificial intelligence. Partnering with SBG allows us to expand our reach and bring our AI-enabled solutions to the Japanese market. Together, we aim to ensure that patients benefit from personalized, data-driven therapies in an effort to help them live longer and healthier lives," Eric Lefkofsky, Tempus Founder and CEO.